# ExoRNA Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exorna-bio

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.exornabio.com
- Latest round: Angel (May 15, 2023)
- Investors on record: 5

## About

Found in 2021 and based in Shanghai, China, ExoRNA Bio is a biotech company that focuses on the development of small RNA nucleic acid drugs, which was established by Chenyu Zhang and Xia Meng. The CSO and Founder, Chenyu Zhang, has over 15 years of research experience in various RNAs and published more than 300 papers in Nature, Science, Cell, and their subsidiaries. The CEO and Co-Founder, Xia Meng, graduated from the University of Paris VI and has published over 30 articles in Clinical Cancer Research, PNAS, and PLoS One. In May 2023, it raised angel + funding from Dingxin Capital, Zhejiang Jingxin Pharmaceuticals,  Nanjing University Biomedical Industry Alumni Association, CDH Investments, etc.

The company engages in the development of delivery platforms and related drugs. The company has a third-generation RNAi drug delivery platform in vivo. The third-generation RNAi drug delivery platform in vivo can cross the blood-brain barrier and overcome the treatment of CNS neurological diseases. Based on bioinformatics, statistics, AI, and gene databases, it has developed the Shengxin analysis platform that can promote the development of small nucleic acid drugs.

## Funding rounds

- Angel, May 15, 2023 — CDH Investments, Yuexiu Industrial Investment Funds Management, Zhejiang Jingxin Pharmaceuticals, Dingxin Capital, Nanjing University Biomedical Industry Alumni Association
- Angel, Feb 7, 2022 — CDH Investments

## Investors

- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Angel
- Yuexiu Industrial Investment Funds Management (https://capitalatlas.ai/funds/yuexiu-industrial-investment-funds-management) — Angel
- Zhejiang Jingxin Pharmaceuticals — Angel
- Dingxin Capital — Angel
- Nanjing University Biomedical Industry Alumni Association — Angel